Jay Umed Sheth
Overview
Explore the profile of Jay Umed Sheth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
88
Followers
0
Related Specialty
Related Specialty
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chakraborty S, Sheth J
Clin Ophthalmol
. 2024 Nov;
18:3343-3351.
PMID: 39582495
Purpose: To evaluate the efficacy of fovea-sparing internal limiting membrane (ILM) peeling combined with ILM plug placement in patients with optic disc pit maculopathy (ODP-M). Patients And Methods: This retrospective...
2.
Chakraborty S, Sheth J
Clin Ophthalmol
. 2024 Oct;
18:2897-2905.
PMID: 39429440
Purpose: This retrospective study aimed to compare the efficacy and safety of intravitreal Dexamethasone Implant (DEX) and Brolucizumab Injection in treating Diabetic Macular Edema (DME) with Hyperreflective Intraretinal Dots (HRID)....
3.
Chakraborty S, Sheth J
Clin Ophthalmol
. 2024 Oct;
18:2865-2871.
PMID: 39398466
Purpose: To evaluate the efficacy and safety of Bevatas, an Indian bevacizumab biosimilar, in the management of both Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO) (BIOS-RVO)....
4.
Chakraborty S, Ganguly S, Sheth J
Clin Ophthalmol
. 2024 Jan;
18:227-233.
PMID: 38283181
Purpose: Diabetic macular edema (DME) is a significant cause of vision impairment, posing challenges in its management due to variable responses and patient diversity. While anti-vascular endothelial growth factor (anti-VEGF)...
5.
Chakraborty S, Sheth J
Clin Ophthalmol
. 2024 Jan;
18:61-68.
PMID: 38205264
Purpose: To evaluate the role of an Indian bevacizumab biosimilar (Bevatas), for the management of type 1 retinopathy of prematurity (ROP) and aggressive posterior ROP (APROP) over 24-weeks. Patients And...
6.
Chakraborty S, Sheth J
Clin Ophthalmol
. 2023 Oct;
17:2871-2877.
PMID: 37808002
Purpose: To analyze the impact of the COVID-19 pandemic on the retinopathy of prematurity (ROP) services at Special Newborn Care Units (SNCUs), which provide care for sick neonates in the...
7.
Chakraborty S, Sheth J
Am J Ophthalmol Case Rep
. 2023 May;
30:101829.
PMID: 37252048
Purpose: To determine the role of intravitreal injection (IVI) of brolucizumab for extra-large pigment epithelial detachment (PED) secondary to macular neovascularization (MNV). Observations: A prospective, non-randomized, uncontrolled case series of...
8.
Chakraborty S, Sheth J
Case Rep Ophthalmol
. 2022 Dec;
13(3):956-962.
PMID: 36466067
The management of submacular hemorrhage (SMH) necessitates rapid clearing of the bleed for optimal visual outcomes. We present a series of 3 cases with large fresh SMH (≤7 days) secondary...
9.
Chakraborty S, Sheth J
Case Rep Ophthalmol Med
. 2022 Jul;
2022:3442306.
PMID: 35874928
A 44-year-old-female with angioid streak- (AS-) associated choroidal-neovascularization (CNV) was treated with one dose of intravitreal brolucizumab (IB). At one-month, the patient's visual acuity (VA) improved from 20/120 to 20/40...
10.